@article{1b36d007ec904260822400eba92919d4,
title = "Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting",
keywords = "Chemoresistance, Immunotherapy, Moonshot, Personalized therapy, Preclinical models, Tumor heterogeneity",
author = "Katherine Fuh and Vlad, \{Anda M.\} and Landen, \{Charles N.\}",
note = "Funding Information: The closing session was highlighted by a speech from Vice President Joe Biden, who discussed the National Cancer Moonshot Initiative, which began on October 21, 2015, to “end cancer as we know it today”. He discussed awareness on how to realign incentives in cancer research, in particular how to incentivize data sharing. As he has toured cancer centers nationally, he learned that ideas which are most “out of the box” are infrequently funded by the NIH. He likened the current system for grant funding to asking Derek Jeter to sell bonds in order to build Yankee Stadium. Research funding has been improving as seen last year with a 2 billion dollar increase for 2016 (the NIH, of which about \$264 million went to the NCI – the moonshot program is targeting 1 billion dollars in dedicated funds, though it is not yet clear from where that money will come). One AACR-sponsored program that was highlighted is Project GENIE (Genomics, Evidence, Neoplasia, Information, Exchange – http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx\#.VyzxSNIrJhE ). This registry contains CLIA-/ISO-certified genomic data to be used in generating research hypotheses spanning translational to clinical studies that can be freely shared and queried by the research community. By working closely with the FDA, this regulatory-grade database could perhaps be accepted as the necessary evidence to gain regulatory approval. ",
year = "2016",
month = jul,
day = "1",
doi = "10.1016/j.ygyno.2016.05.013",
language = "English",
volume = "142",
pages = "9--12",
journal = "Gynecologic oncology",
issn = "0090-8258",
number = "1",
}